上皮性卵巢癌35年前瞻性注册数据的临床病理特征与结局模式
基于苏格兰东南部1981—2015年2805例卵巢癌患者的前瞻性注册数据,分析35年间临床病理特征与疾病特异性生存变化。结果显示疾病特异性生存显著改善(中位1.73年 vs 4.23年,P<0.0001),但无进展生存无显著变化(中位1.22年 vs 1.58年,P=0.2568),提示结局改善主要来自复发后生存延长。
要点
- 疾病特异性生存从1981—1985年的中位1.73年增至2011—2015年的4.23年(P<0.0001)。
- 无进展生存无显著改善(中位1.22年 vs 1.58年,P=0.2568)。
- 减瘤术后低残留病灶(<2 cm)比例从54.0%升至87.7%(P<0.0001)。
核心结论
- 卵巢癌疾病特异性生存过去35年显著改善,但改善主要限于复发后生存延长而非无进展生存。
研究设计与样本
- 基于注册的前瞻性收集数据,纳入1981—2015年苏格兰东南部诊断的2805例卵巢癌患者。
- 采用Kaplan-Meier法可视化生存时间,并用中位生存、5年生存概率及限制性平均生存时间分析量化差异。
主要发现
- 疾病特异性生存从1981—1985年至2011—2015年显著增加(中位1.73年 vs 4.23年,P<0.0001)。
- 无进展生存相应增加无统计学意义(中位1.22年 vs 1.58年,P=0.2568)。
- 减瘤术后低残留病灶(<2 cm)比例从54.0%升至87.7%(P<0.0001)。
- 高级别浆液性癌比例增加(P<0.0001),子宫内膜样癌和黏液性癌比例下降(P=0.0005和P=0.0002)。
- IV期高级别浆液性癌发病率增加(P=0.0009)且其疾病特异性生存改善(P=0.0122)。
关键数值与推荐
- 组织学类型、分期、残留病灶和ECOG体能状态仍是可靠的结局预测因素。
- 诊断中位年龄增加与ECOG体能状态随时间增加相关(r=0.86)。
临床怎么用
- 临床应关注复发后生存延长是当前结局改善的主要来源,需优化复发后治疗策略。
- 减瘤术后低残留病灶比例大幅提升,支持持续追求最小或零残留病灶的减瘤目标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Investigate the clinical landscape of ovarian carcinoma (OC) over time. DESIGN: Register-based prospectively collected data. SETTING: South East Scotland. SAMPLE: A total of 2805 OC patients diagnosed in 1981-2015. METHODS: Survival times were visualised using the Kaplan-Meier method; median survival, 5-year survival probabilities and associated restricted mean survival time analyses were used to quantify survival differences. MAIN OUTCOME MEASURES: Disease-specific survival. RESULTS: A significant increase in disease-specific survival (DSS) from 1981-1985 to 2011-2015 was observed (median 1.73 versus 4.23 years, P < 0.0001). Corresponding increase in progression-free survival (PFS) was not statistically significant (median 1.22 versus 1.58 years, P = 0.2568). An increase in the proportion of cases with low residual disease volume (RD) (<2 cm RD) following debulking was observed (54.0% versus 87.7%, P < 0.0001). The proportion of high grade serous (HGS) cases increased (P < 0.0001), whereas endometrioid and mucinous cases decreased (P = 0.0005 and P = 0.0002). Increases in stage IV HGS OC incidence (P = 0.0009) and stage IV HGS OC DSS (P = 0.0122) were observed. Increasing median age at diagnosis correlated with increasing Eastern Cooperative Oncology Group Performance Status (ECOG PS) over time (r = 0.86). CONCLUSIONS: OC DSS has improved over the last 35 years. PFS has not significantly increased, highlighting that improvement in outcome has been limited to extending post-relapse survival. Distribution of stage at diagnosis, histological subtype and RD following debulking has changed over time, reflecting evolution in tumour classification, staging and optimal debulking definitions (from low RD to minimal or zero RD). Histology, stage, RD and ECOG PS remain reliable outcome predictors. Increasing median age at diagnosis and ECOG PS indicates demographic shifts in the clinical population. TWEETABLE ABSTRACT: Significant improvement in ovarian carcinoma survival has been seen over time. Most of this improvement is due to an extension of survival following disease relapse.
引用
- Irodi A, Rye T, Herbert K, et al. Patterns of clinicopathological features and outcome in epithelial ovarian cancer patients: 35 years of prospectively collected data. BJOG. 2020. PMID: 32285600. doi:10.1111/1471-0528.16264
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。